FORM 4

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-0287							
Estimated average burden							
hours per response:	0.5						

	tion 1(b).			Fi	led pur or	suant Sect	to Section 30	ction 16(a (h) of the	a) of the s Investm	Secur ent Co	ities Exchan ompany Act	ge Act of 1 of 1940	934		llouis	per re	эропъе.	0.5
1. Name and Address of Reporting Person* THOMSON DAVID S.					2. Issuer Name and Ticker or Trading Symbol PRECISION BIOSCIENCES INC [DTIL]] (Ch	eck all applic	cable) or	109		vner	
(Last) (First) (Middle) C/O PRECISION BIOSCIENCES, INC. 302 E. PETTIGREW STREET, SUITE A-100						3. Date of Earliest Transaction (Month/Day/Year) 06/11/2021								A below)	(give title Other (sp below) nief Operating Officer		specify	
(Street) DURHA (City)			27701 (Zip)		_ 4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	e) X Form f Form f	ividual or Joint/Group Filing (Check Applicable Form filed by One Reporting Person Form filed by More than One Reporting Person				
		Tab	le I - No	n-Deri	vativ	e Se	curi	ties Ac	quirec	l, Di	sposed o	f, or Be	neficial	ly Owned				
1. Title of Security (Instr. 3) 2. Trans: Date (Month/t			Execution D		on Date,	3. Transaction Code (Instr. 8)				Benefici	es For ally (D) Following (I) (n: Direct or Indirect nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
									Code	v	Amount	(A) or (D)	Price	Transaci (Instr. 3	tion(s)			(111301. 4)
Common	Stock			06/11	L/2021				М		30,000	A	\$1.18	141,	1,513 ⁽¹⁾ D			
Common	Stock			06/11	L/2021	L			S		30,000	D	\$11.52	1.52 ⁽²⁾ 111,513 D				
		7	Гаble II -								osed of, convertil			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year	Date,	4. Transactio Code (Inst 8)				6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction((Instr. 4)	e s Illy	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Date Exercis	able	Expiration Date	Title	Amount or Number of Shares					
Employee Stock Option (Right to	\$1.18	06/11/2021			M			30,000	(3)		06/29/2027	Common Stock	30,000	\$0.00	87,11	3	D	

Explanation of Responses:

- 1. Includes 2,270 additional shares acquired under the Company's 2019 Employee Stock Purchase Plan since the Reporting Person's ownership report filed on January 25, 2021.
- 2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$11.50 to \$11.68. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 3. The option is fully vested and exercisable.

Remarks:

/s/ Dario Scimeca, Attorney-in-Fact for David S. Thomson

06/15/2021

** Signature of Reporting Person

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.